摘要
Gliomas,the most common primary tumors in the central nervous system(CNS),can be categorized into 4 grades according to the World Health Organization.The most malignant glioma type is gradeⅣ,also named glioblastoma multiforme(GBM).However,the standard treatment of concurrent temozolomide(TMZ)chemotherapy and radiotherapy after maximum resection does not improve overall survival in patients with GBM.Targeting components of the CNS microenvironment represents a new strategy for improving the efficacy of glioma treatment.Most recent studies focused on T cells.However,there is a growing body of evidence that tumor-associated macrophages(TAMs)play an important role in tumor progression and can be regulated by a wide array of cytokines or chemokines.New TAM-associated immunotherapies may improve clinical outcomes by blocking tumor progression and prolonging survival.However,understanding the exact roles and possible mechanisms of TAMs in the tumor environment is necessary for developing this promising therapeutic target and identifying potential diagnostic markers for improved prognosis.This review summarizes the possible interactions between TAMs and glioma progression and discusses the potential therapeutic directions for TAM-associated immunotherapies.
作者简介
Yichen Peng is pusueing her Bachelorʹs degree in Capital Medical University,China.Currently,her research focuses on the comprehensive treatment of brain tumors.E‐mail:pengyichen0429@qq.com;Feng Chen received her Ph.D.degree from Shandong Medical University,China(1999).She is now a chief physician and professor in Beijing Tiantan Hospital,Capital Medical University.She has published over thirty papers on core Chinese journals and SCI journals.She is a member of the Tumor Immunonutrition Group of Chinese Society for Oncological Nutrition and Support Care.Her current research interests focus on the pathogenesis and treatment of malignant tumors,especially brain tumors.Email:chenfeng@bjtth.org;Shenglan Li received her Ph.D.degree from the Department of Biochemistry and Molecular Biology,School of Basic Medical Sciences,Capital Medical University,China,in July 2019.Now she works as a post‐doctor in the Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,China.Her research focuses on the invasion and metastasis mechanisms of cancer.E‐mail:lishenglan_0405@163.com;Xiu Liu received her Bachelorʹs degree in Southern Medical University,China,in July 2014.Now she is a Ph.D.candidate at Capital Medical University,China.Her research focuses on the immune microenvironment and immunotherapy of glioma.E‐mail:liuxiu0313@sina.com;Can Wang received his B.S.Med.degree from Hunan University of Chinese Medicine in July 2017.Now he is a Ph.D.candidate in Capital Medical University.His research focuses on understanding how glioma cells interact with tumor microenvironment on glioma prognosis.E‐mail:wangkxj@ccmu.edu.cn;Chunna Yu received her Masterʹs degree from Capital Medical University in July 2019.Now he is a Ph.D.candidate in Capital Medical University.Her current research interests focus on immunotherapy for malignant glioma.E‐mail:ycnwork@163.com;Corresponding author:Wenbin Li received his Ph.D.degree from Beijing Tiantan Hospital,China(2011).He was a research fellow in University of South Florida(1999–2003)and Moffitt Cancer Center(2003–2005),and is currently a professor in Beijing Tiantan Hospital(2018).He has published over fifty articles on SCI and core Chinese journals.Currently,he focuses on comprehensive treatment of brain tumors and clinical trials of innovative drugs for gliomas and cancer immunotherapies.He is the deputy director of the Clinical and Research Center of Glioma,Capital Medical University.E‐mail:liwenbin@ccmu.edu.cn
